CME: The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management

Overview
Achieving LDL-c targets is a very important goal in patients at risk of cardiovascular disease. Unfortunately, the majority of high- and very high-risk patients do not achieve guideline recommended LDL-c goals. In this series, four experts discuss the need and challenges to reach LDL-c targets and talk about various LDL-c lowering therapies.
This course consists of 4 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of four presentations on LDL-c-lowering therapies
The evolving need and challenges to reach LDL-c targets in high-risk patients - Kausik Ray, MD - London, UK
- According to the latest registries, the majority of high- and very high-risk patients do not achieve the 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.
Oral cholesterol-lowering therapies: The basis of prevention - Lale Tokgözoğlu, MD - Ankara, Turkey
- "Oral cholesterol-lowering therapies are the basis of cardiovascular disease prevention", says Lale Tokgözoğlu. In this video, she talks about oral therapies.
PCSK9i: Benefits across the spectrum of cardiovascular disease - Fabrice Martens, MD, PhD - Amsterdam, The Netherlands
- Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.
Novel oral pathways in LDL-c lowering therapy: The new promise of CETPi - Erin Michos, MD - Baltimore, MD, USA
- Erin Michos talks about CETPi as a novel opportunity for oral LDL-c lowering therapy. She explains the mechanism of action of CETPi and discusses past and ongoing studies with CETPi.
Instructions
- Watch the four lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@pace-cme.org.
Learning Objectives
- Describe the current challenges to reach LDL-c targets in high-risk patients
- Memorize the expected LDL-c reductions with oral combination therapy
- Summarize the effects of PCSK9 monoclonal antibodies
- Recall the effects of CETPi on the lipid profile
Target Audience
This educational activity is designed for all healthcare professionals with an interest in management of patients with elevated LDL-c.
Accreditation and Credit Designation Statements
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from Amgen, NewAmsterdam Pharma, Sanofi and Viatris.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/12/2023
Expiration Date: 04/12/2025